DUBLIN--(BUSINESS WIRE)--The "Vietnam Tuberculosis Therapeutics Market, By Disease Type (Active Tuberculosis v/s Latent Tuberculosis), By Therapy (First Line Therapy v/s Second Line Therapy), By Region, Competition Forecast & Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

The Vietnam tuberculosis therapeutics market is anticipated to register a robust growth in the forecast period, 2023-2027. Growing demands for effective treatment and efficient pharmaceuticals to control the growing instances of tuberculosis is driving the market growth.

Besides, increasing investments and grants for tuberculosis therapeutics are boosting the growth of the Vietnam tuberculosis therapeutics market. Earlier, tuberculosis has been a leading cause of death in Vietnam. The government is aggressively implementing programs and initiatives to control the tuberculosis rates such as the National Tuberculosis Control Programme (NTP).

Rising government measures and growing public awareness of communicable illnesses are also expected to fuel the Vietnam tuberculosis therapeutics market. Rising incidences of drug susceptible tuberculosis and increase in multi-drug resistant TB cases are some of the factors boosting the market growth. Besides. More R&D efforts towards drug development, emergence of effective drug alternatives in the market, and collaborations focused on the development of shorter treatment regimens to fight resistance and address unmet medical needs, which are expected to fuel the market growth.

The Vietnam tuberculosis therapeutics market is segmented on the basis of disease type, therapy, competitive landscape, and regional distribution. Based on disease type, the market is divided between active tuberculosis and latent tuberculosis. The most common cause of tuberculosis in the general population is Mycobacterium tuberculosis.

The prevalence of Mycobacterium tuberculosis in South Asian nations like Vietnam, India, Laos, etc., is a significant contributor to the rise in tuberculosis cases and, consequently, the demand for tuberculosis medicines. Active tuberculosis patients have a propensity to spread the illness to others. Patients with latent tuberculosis, however, do not have this tendency.

Years considered for this report:

• Historical Years: 2017-2020
• Base Year: 2021
• Estimated Year: 2022
• Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth in the market size of the Vietnam tuberculosis therapeutics from 2017 to 2021.
• To estimate and forecast the market size of Vietnam tuberculosis therapeutics market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the Vietnam tuberculosis therapeutics market based on disease type, therapy, region, and company.
• To identify the dominant region or segment in the Vietnam tuberculosis therapeutics market.
• To identify drivers and challenges for the Vietnam tuberculosis therapeutics market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Vietnam tuberculosis therapeutics market.
• To identify and analyze the profiles of leading players operating in the Vietnam tuberculosis therapeutics market.
• To identify key sustainable strategies adopted by market players in Vietnam tuberculosis therapeutics market.

Companies Mentioned

• Novartis Vietnam Co., Ltd.
• Johnson & Johnson
• Otsuka Pharmaceutical Vietnam JSC
• Lupin Limited
• GSK Vietnam

Report Scope:

In this report, Vietnam tuberculosis therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Vietnam Tuberculosis Therapeutics Market, By Disease Type:

• Active Tuberculosis
• Latent Tuberculosis

Vietnam Tuberculosis Therapeutics Market, By Therapy:

• First Line Therapy
• Second Line Therapy

Vietnam Tuberculosis therapeutics Market, By Region:

• Northern Region
• Central Region
• Southern Region

For more information about this report visit https://www.researchandmarkets.com/r/9sgnr6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900